AN2 Therapeutics, Inc.
ANTX
$1.26
-$0.02-1.56%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.73% | 1.10% | 5.89% | -2.74% | 15.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.66% | 2.32% | 25.11% | 42.03% | 64.77% |
| Operating Income | 21.66% | -2.32% | -25.11% | -42.03% | -64.77% |
| Income Before Tax | 20.72% | -1.71% | -19.06% | -35.79% | -58.05% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.72% | -1.71% | -19.06% | -35.79% | -58.05% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.72% | -1.71% | -19.06% | -35.79% | -58.05% |
| EBIT | 21.66% | -2.32% | -25.11% | -42.03% | -64.77% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 38.98% | 28.86% | 19.18% | -2.98% | 40.01% |
| Normalized Basic EPS | 41.64% | 31.48% | 19.18% | -2.98% | 31.70% |
| EPS Diluted | 38.98% | 28.86% | 19.18% | -2.98% | 40.01% |
| Normalized Diluted EPS | 41.64% | 31.48% | 19.18% | -2.98% | 31.70% |
| Average Basic Shares Outstanding | 26.57% | 42.06% | 48.19% | 35.29% | 54.18% |
| Average Diluted Shares Outstanding | 26.57% | 42.06% | 48.19% | 35.29% | 54.18% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |